IDRSF News and Press, Idorsia AG From 02/04/23

Summary Idorsia is a Swiss biopharmaceutical company with multiple commercial and pre-commercial assets. Idorisa's lead asset Daridorexant seems to be a more attractive option compared to SOC in Isomnia due to lower a) drug abuse, b) withdrawal symptoms, and c) rebound insomnia. The...

Summary I will list major press events shared by Idorsia in 2022. I will offer my readers my personal commentary about each event. I will recap 2022 and comment on what is expected in 2023. Prelude I shared my first article on Idorsia ([[IDRSF]] and IDIA.SW) on Jul...

Summary Idorsia’s stock is testing its most important overhead resistance and is trying to break out from its long-term downtrend, a rare situation that could lead to significant upside potential. The company has recently reported strong phase 3 results from one of the most...

The following slide deck was published by Idorsia Ltd in conjunction with this event. For further details see: Idorsia (IDRSF) Investor Presentation - Slideshow

Idorsia Ltd (IDSRF) Q3 2022 Results Conference Call October 25, 2022 08:00 AM ET Company Participants Andrew Weiss - IR Jean-Paul Clozel - CEO Simon Jose - Chief Commercial Officer André Muller - CFO Conference Call Participants Manos Mastora...

Idorsia press release ( OTCPK:IDRSF ): Q3 Non-GAAP EPS of -CHF1.22. Revenue of CHF21M (+23.5% Y/Y) misses by CHF6.65M . For further details see: Idorsia Non-GAAP EPS of -CHF1.22, revenue of CHF21M misses by CHF6.65M

Summary Q2 results are on the table and Idorsia could convince with encouraging developments in its pipeline and its initial commercial efforts with QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan). The Swiss and Canadian health authorities are supposed to give their feedback on QU...

Idorsia Ltd (IDRSF) H1 2022 Earnings Conference Call July 26, 2022 08:00 AM ET Company Participants Jean-Paul Clozel - CEO André Muller - CFO Simon Jose - CCO Andrew Weiss - Head of IR Conference Call Participants Peter Verdult - Citi Jam...

The following slide deck was published by Idorsia Ltd in conjunction with their 2022 Q2 earnings call. For further details see: Idorsia Ltd 2022 Q2 - Results - Earnings Call Presentation

Idorsia press release ( OTCPK:IDRSF ): Q2 GAAP EPS of -CHF1.25. Revenue of CHF17M (+142.9% Y/Y). CFO comment: “Idorsia has reached another important milestone by recording its first product sales with the launches of PIVLAZ in Japan and QUVIVIQ in the US. ...